Organon & Co. (NYSE:OGN), a prominent player ... provides easy-to-follow model portfolios designed for wealth accumulation. Curious if OGN is one of these AI-selected gems? Check out our ProPicks ...

After a rigorous selection process, the Desjardins Group Board of Directors is pleased to announce that Denis Dubois has been appointed as President and CEO. He will step into this role on September 2 ...

Gateway Fleets, the electrification platform purpose-built for last-mile delivery, today announced the opening of its newest electric vehicle charging depot in Riverside, California. Built in just ...

Organon was then acquired by Schering-Plough ... another area that has been poorly served by the pharma R&D investment model as returns on such drugs are usually low. Catriona Crombie, fund ...

Story April 9 - Organon: The women’s health drugmaker ... Novartis is making to its cardiovascular commercialization model that are designed to “simplify and strengthen” how the drugmaker ...

United States-based pharmaceutical company Organon announces its official business launch in ... with other businesses and the pan-ecological circle to create our own model covering products, service, ...

Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue ...

A still from the "Rromantasy" commercial (Organon) The ad ends with a final nod to the genre, with the claim that Nexplanon is “over 99% effective, no matter the fantasy.” Organon pledges $30M ...

Organon saw significant volatility last month with a 30% decline in its share price, coinciding with the company's announcement of decreased earnings and a reduction in its dividend payout.

We recently published a list of These 10 Firms Are On Fire Today. In this article, we are going to take a look at where Organon & Co.’s (NYSE:OGN) stands against other stocks that surged yesterday.

Initiate Strong Buy on Organon & Co. with $26.4 PT, driven by cost savings, Nexplanon momentum, and biosimilars diversification offsetting Established Brands LOE. Forecasted EPS of $4.00 (FY25 ...

GLOBAL healthcare company Organon recently hosted a forum titled "Women's Health Unveiled: Insights into Hormonal Shifts and Unplanned Pregnancies", shedding light on two often-overlooked yet critical ...